scPharmaceuticals Inc. Reports Third Quarter 2024 Financial …

4 days ago · The increase in net loss for the third quarter of 2024, was primarily due to one-time charges related to the extinguishment of debt and accounting for the new financial instruments …

CouponFollow Extension

$91
OFF

ScPharmaceuticals Inc. Reports Third Quarter 2024 Financial

1 week from now

3 days ago · scPharmaceuticals ended the third quarter of 2024 with $91.5 million in cash and cash equivalents, compared to $76.0 million in cash, cash equivalents, and short-term …

biospace.com

24%
OFF

ScPharmaceuticals Inc. Reports Third Quarter 2024 Financial …

1 week from now

4 days ago · For the third quarter ended September 30, 2024, scPharmaceuticals reports: Net FUROSCIX revenue of $10.0 million, representing a 24% increase from the second quarter of …

yahoo.com

$91
OFF

ScPharmaceuticals Inc. Reports Third Quarter 2024 Financial …

1 week from now

4 days ago · scPharmaceuticals ended the third quarter of 2024 with $91.5 million in cash and cash equivalents, compared to $76.0 million in cash, cash equivalents, and short-term …

manilatimes.net

164%
OFF

ScPharmaceuticals Inc. (SCPH) - Stock Analysis

1 week from now

2 days ago · scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update. Generated 3Q 2024 net FUROSCIX ® revenue of $10.0 million, up 164% …

stockanalysis.com

164%
OFF

ScPharmaceuticals Inc. Reports Third Quarter 2024 Financial …

1 week from now

4 days ago · Generated 3Q 2024 net FUROSCIX®revenue of $10.0 million, up 164% from Q3 2023 scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides …

bakersfield.com

164%
OFF

ScPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results

1 week from now

4 days ago · For the third quarter ended September 30, 2024, scPharmaceuticals reported a net revenue of $10.0 million from its FUROSCIX® product, marking a 164% increase from the …

tradingview.com

$0.44
OFF

ScPharmaceuticals (SCPH) Earnings Date And Reports 2024

1 week from now

2 days ago · scPharmaceuticals announced Q2 2024 earnings on August 14, 2024, reporting an EPS of -$0.44, which hit analysts' consensus estimates of -$0.44. Quarterly revenue was …

marketbeat.com

$8
OFF

ScPharmaceuticals Inc. Reports Second Quarter 2024 Financial …

1 week from now

Aug 14, 2024 · Business Update. For the second quarter ended June 30, 2024, scPharmaceuticals reports: Net FUROSCIX revenue of $8.1 million. Approximately 9,300 …

yahoo.com

$64
OFF

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial …

1 week from now

5 days ago · Net Loss: Net loss for the third quarter of 2024 was $64.8 million, or $0.18 per share, as compared to a net loss of $50.5 million, or $0.21 per share, in the corresponding period in …

morningstar.com

8%
OFF

Molina Healthcare Reports Third Quarter 2024 Financial Results

1 week from now

Oct 23, 2024 · Quarter Highlights. As of September 30, 2024, the Company served approximately 5.6 million members, an increase of 8% compared to September 30, 2023.; Premium revenue …

molinahealthcare.com

$91
OFF

ScPharmaceuticals Inc. Reports Third Quarter 2024 Financial

1 week from now

4 days ago · scPharmaceuticals ended the third quarter of 2024 with $91.5 million in cash and cash equivalents, compared to $76.0 million in cash, cash equivalents, and short-term …

globenewswire.com

$91
OFF

ScPharmaceuticals Inc. Reports Third Quarter 2024 Financial Resu

1 week from now

4 days ago · scPharmaceuticals ended the third quarter of 2024 with $91.5 million in cash and cash equivalents, compared to $76.0 million in cash, cash equivalents, and short-term …

gurufocus.com

$14
OFF

Tonix Pharmaceuticals Reports Third Quarter 2024 Financial …

1 week from now

5 days ago · Net loss available to common stockholders was approximately $14.2 million, or $0.23 per share, basic and diluted, for the third quarter 2024, compared to net loss available to …

businessinsider.com

$3
OFF

Cyclacel Pharmaceuticals Reports Third Quarter Financial ... - Nasdaq

1 week from now

5 days ago · As of September 30, 2024, cash equivalents totaled $3.0 million, compared to $3.4 million as of December 31, 2023. Net cash used in operating activities was $6.6 million for the …

nasdaq.com

70%
OFF

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial …

1 week from now

In the third quarter of 2024, revenue of $23.3 million, or 70% of product revenue, was generated in the United States, an increase of 8% on a sequential basis; revenue of $10.0 million, or 30% …

yahoo.com

77%
OFF

Hims & Hers Health, Inc. Reports Third Quarter 2024 Financial …

1 week from now

Nov 4, 2024 · Third Quarter 2024 Financial Highlights Revenue was $401.6 million for the third quarter of 2024 compared to $226.7 million for the third quarter of 2023, an increase of 77% …

yahoo.com

FAQs about scPharmaceuticals Inc. Reports Third Quarter 2024 Financial … Coupon?

How did scpharmaceuticals perform in the second quarter of 2024?

scPharmaceuticals reported a net loss of $17.1 million for the second quarter of 2024, compared to $14.2 million for the second quarter of 2023. scPharmaceuticals ended the second quarter of 2024 with $38.5 million in cash, cash equivalents and short-term investments, compared to $76.0 million as of December 31, 2023. ...

What time is scpharmaceuticals' conference call & webcast?

scPharmaceuticals’ management will host a conference call and webcast to review the Company’s second quarter 2024 results today, Wednesday, August 14, at 4:30 p.m. EDT. Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13747259. ...

What did Rhythm Pharmaceuticals do in Q3 2024?

ET -- BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today reported financial results and provided a business update for the third quarter ended September 30, 2024. ...

What did Marinus Pharmaceuticals do in the third quarter 2024?

RADNOR, Pa., November 12, 2024 -- (BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2024. ...

How did premium revenue perform in the third quarter of 2024?

Premium revenue was approximately $9.7 billion for the third quarter of 2024, an increase of 18% year over year. GAAP net income was $5.65 per diluted share for the third quarter of 2024, an increase of 34% year over year. Adjusted net income was $6.01 per diluted share for the third quarter of 2024, an increase of 19% year over year. ...

Does scpharmaceuticals have PK/PD data for autoinjector?

PK/PD Data for Autoinjector: In August 2024, scPharmaceuticals announced positive PK/PD data that met all primary and secondary endpoints. scPharmaceuticals is continuing to progress towards its targeted submission of a Supplemental New Drug Application (sNDA) to the FDA by the end of January 2025. ...